Bluebird joins the layoff flock to reality as gene therapy biotech sheds staff to save itself
Bluebird bio is laying off about 30% of its workforce to save itself before the FDA decides the fate of two of its gene therapies in August and September and plans to file for a third approval in the first quarter of next year.
The dire situation came into clear view earlier this year when bluebird said in a quarterly filing its cash problems “raise substantial doubt regarding its ability to continue as a going concern” in the coming year. The CFO resigned the same day.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.